Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Teprasiran (Primary)
- Indications Acute kidney injury
- Focus Registrational; Therapeutic Use
- Sponsors Quark Pharmaceuticals
- 12 Jul 2021 Status changed from active, no longer recruiting to discontinued early for one year follow up due to results not meeting efficacy outcome at Day 90.
- 01 May 2021 This trial has been discontinued in Austria, as per European Clinical Trials Database record.
- 13 Mar 2021 As per Eudra update record, this trial has been completed in Belgium.